Sign in
WithdrawnNo phase

Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)

Key facts

Who runs it
Huashan Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
1 Oct 2024
Ended
30 Dec 2025
Type of study
Observational, 4 groups
Treatments tested
  • Biomarker assay
Record updated
19 March 2025
Why it stopped
Our applied project did not receive funding support, so it cannot proceed, leading to the withdrawal of the study.

Who can take part

Age
50 years to 75 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (48)Hide the full registry criteria

Who can take part

  • Clinical diagnosis of "probable PD" by two neurologists specializing in movement disorders according to the International Parkinson and Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PD (2015)
  • Age 50-75, disease duration is less than 1 year, and Hoehn \& Yahr Stage I
  • the dopamine reuptake transporter (DAT) is significantly reduced in striatum on PET imaging
  • Metabolic brain network detected by fluorine-18-labelled-fluorodeoxyglucose-PET(18F-FDG PET) is consistent with Parkinson's disease-related pattern (PDRP), with FDG hypermetabolism being in basal ganglia and cerebellum
  • Good response to anti-PD medications
  • Ability of completing questionnaires
  • Ability of providing informed consent
  • Willingness of being assessed by neurologists during off-medication state defined as discontinuing anti-PD medications for at least 12 hours before assessment
  • Clinical diagnosis of "probable MSA" by two neurologists specializing in movement disorders according to the International Parkinson and Movement Disorder Society (MDS) second consensus criteria for MSA (2019)
  • Age 50-75, and disease duration is less than 1 year
  • Metabolic brain network detected by fluorine-18-labelled-fluorodeoxyglucose-PET(18F-FDG PET) is consistent with MSA related pattern
  • Ability of completing questionnaires
  • Ability of providing informed consent
  • Willingness of being assessed by neurologists during off-medication state defined as discontinuing anti-PD medications for at least 12 hours before assessment
  • Clinical diagnosis of "probable PSP" by two neurologists specializing in movement disorders according to MDS Clinical Diagnostic Criteria for PSP (2017)
  • Age 50-75, disease duration is less than 1 year
  • Metabolic brain network detected by fluorine-18-labelled-fluorodeoxyglucose-PET(18F-FDG PET) is consistent with PSP related pattern
  • Ability of completing questionnaires
  • Ability of providing informed consent
  • Willingness of being assessed by neurologists during off-medication state defined as discontinuing anti-PD medications for at least 12 hours before assessment
  • Age 50-75
  • No history of neurodegenerative disease of the central nervous system
  • No history of infective disease of the central system
  • Ability of completing questionnaires
  • Ability of providing informed consent

Who cannot take part

  • Secondary parkinsonism (ie. drug induced)
  • Secondary parkinsonism (ie. drug induced)
  • Secondary parkinsonism (ie. drug induced)
  • History of being diagnosed as any cancer within 5 years
  • Presence of any condition risking the procedure of performing lumbar puncture (LP)
  • History of being diagnosed as any cancer within 5 years
  • Presence of any condition risking the procedure of performing lumbar puncture (LP)
  • History of being diagnosed as any cancer within 5 years
  • Presence of any condition risking the procedure of performing lumbar puncture (LP)
  • Inability to comply with study procedures; For controls without diagnosis of neurodegenerative disorders
  • With prodromal symptoms of PD, such as rapid eye movement sleep behavior disorder (RBD)
  • History of being diagnosed as any cancer within 5 years
  • Presence of any condition increasing the risk of the procedure of performing lumbar puncture (LP)
  • Atypical parkinsonisms like MSA or PSP etc
  • Presence of any item in 10 red flags of the MDS Clinical Diagnostic Criteria for PD (2015) in the comprehensive assessments during follow-up
  • Pregnancy
  • Inability to comply with study procedures; For early MSA patients
  • Pregnancy
  • Inability to comply with study procedures; For PSP patients
  • Pregnancy
  • Pregnancy
  • Inability to comply with study procedures

Other criteria

  • For early PD patients

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study will investigate the biomarker of a-synuclein aggregate in CSF detected by protein misfolding cyclic amplification (PMCA) and its sensitivity and specificity in diagnosing Parkinson's disease at H-Y stage I and disease duration less than 1 year, compared with that from age-matched controls without neurodegeneration, those with Multiple System Atrophy (MSA) as a disease control with a-synucleinopathy, and those with Progressive Supranuclear Palsy (PSP) as a control with non-a-synucleinopathy neurodegeneration.

The 4 groups in the trial

  • Parkinson's Disease

    Subjects who have a PD diagnosis

    Treatment: Biomarker assay

  • Multiple System Atrophy

    Subjects who have an MSA diagnosis

    Treatment: Biomarker assay

  • Progressive Superanuclear Palsy

    Subjects who have a PSP diagnosis

    Treatment: Biomarker assay

  • Age-matched controls

    Subjects who do not have a diagnosed neurological disorder

    Treatment: Biomarker assay

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
19 March 2025